FDA Guidance Boosts Legend Biotech's Market Prospects
Legend Biotech Corp's stock has hit a 52-week low, declining by 15.20% in regular trading.
The recent FDA draft guidance allowing minimal residual disease and complete response as endpoints for accelerated approval in multiple myeloma treatments has generated optimism in the market. This is particularly beneficial for Legend Biotech, which is collaborating with Johnson & Johnson on the Carvykti cell therapy, incorporating MRD negativity as an endpoint in the CARTITUDE-6 trial. Analysts from Jefferies have maintained an Outperform rating on Legend Biotech, setting a target price of $66, indicating confidence in its future growth despite current price challenges.
The implications of the FDA guidance could enhance Legend Biotech's competitive position in the market, especially as it aligns with ongoing clinical trials and partnerships that may drive future stock performance.
Trade with 70% Backtested Accuracy
Analyst Views on LEGN
About LEGN
About the author
Legend Biotech (LEGN) Q4 2025 Earnings Transcript
Legend Biotech (LEGN) Q4 2024 Earnings Transcript
Legend Biotech (LEGN) Q2 2025 Earnings Transcript
Legend Biotech (LEGN) Q1 2025 Earnings Transcript
Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates
Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.
EEMA Stock Price Fluctuation and ETF Dynamics
- Price Range Analysis: EEMA's 52-week low is $63.50 per share, with a high of $107.9984, and the latest trade at $96.12 indicates significant price fluctuations that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) operate similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows or outflows, allowing investors to assess the impact on underlying assets and make informed investment decisions.
Legend Biotech (LEGN) Q4 2025 Earnings Transcript
Legend Biotech (LEGN) Q4 2024 Earnings Transcript
Legend Biotech (LEGN) Q2 2025 Earnings Transcript
Legend Biotech (LEGN) Q1 2025 Earnings Transcript
Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates
Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.
EEMA Stock Price Fluctuation and ETF Dynamics
- Price Range Analysis: EEMA's 52-week low is $63.50 per share, with a high of $107.9984, and the latest trade at $96.12 indicates significant price fluctuations that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) operate similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows or outflows, allowing investors to assess the impact on underlying assets and make informed investment decisions.
